湖北广济药业将回购注销11.97万股限制性股票 注册资本减少11.97万元

Core Viewpoint - Hubei Guangji Pharmaceutical Co., Ltd. announced a repurchase and cancellation of 119,700 restricted stocks due to the departure of five incentive targets, leading to a reduction in registered capital and total share capital [1][2]. Group 1: Repurchase and Cancellation Details - The decision to repurchase and cancel the restricted stocks was approved during the 14th temporary meeting of the 11th Board of Directors on January 9, 2026, and subsequently at the first temporary shareholders' meeting on January 27, 2026 [2]. - The repurchase involves stocks granted under the 2021 restricted stock incentive plan, which are no longer eligible for the five departing employees [2]. Group 2: Capital Changes - Following the repurchase, the total share capital will decrease from 346,750,339 shares to 346,630,639 shares, and the registered capital will reduce from 346,750,339 yuan to 346,630,639 yuan, a decrease of 119,700 yuan [3]. Group 3: Creditor Notification and Claims - The company has notified creditors about the reduction in registered capital, allowing them to claim debts or request guarantees within 30 days of receiving the notice or within 45 days from the announcement date if no notice is received [4]. - Specific arrangements for creditors include submission of claims within 45 days, with detailed requirements for documentation and contact information provided [5]. Group 4: Additional Information - The company has published further details regarding the repurchase and cancellation in the official announcement on designated information disclosure platforms [6].